| CAS NO: | 286930-03-8 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 527.65 |
|---|---|
| Formula | C26H37NO3.C4H4O4 |
| CAS No. | 286930-03-8 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (189.5 mM) |
| Water: 100 mg/mL (189.5 mM) | |
| Ethanol: 100 mg/mL (189.5 mM) | |
| Other info | Chemical Name: (E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate InChi Key: MWHXMIASLKXGBU-RNCYCKTQSA-N InChi Code: InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1 SMILES Code: O=C(O)/C=C/C(O)=O.CC(C)C(OC1=CC=C(CO)C=C1[C@@H](C2=CC=CC=C2)CCN(C(C)C)C(C)C)=O |
| Synonyms | SPM-907; SPM907; Fesoterodine, Toviaz, SPM-907 |
| In Vitro | In vitro activity: Fesoterodine is rapidly and extensively converted to 5-HMT, such that the pharmacologic activity appears to be primarily attributable to 5-HMT. Fesoterodine is a competitive antagonist of cholinergic agonist-stimulated responses in human M1-M5 cell lines and has a similar potency and selectivity profile to the radioligand-binding studies. Fesoterodine causes a rightward shift of the concentration-response curve for carbachol with no depression of the maximum in rat bladder strips, and concentration-dependently reduces contractions induced by electrical field stimulation (EFS). Fesoterodine is hydrolyzed by nonspecific esterases to 5-hydroxmethyl tolterodine (5-HMT), which is the active metabolite and is responsible for all its antimuscarinic activity. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Curr Med Chem. 2009;16(33):4481-9; BJU Int. 2008 Apr;101(8):1036-42. |
m.cnreagent.com